These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34142533)

  • 41. Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (M
    Kumar SB; Krishna S; Pradeep S; Mathews DE; Pattabiraman R; Murahari M; Murthy TPK
    Comput Biol Med; 2021 Jul; 134():104524. PubMed ID: 34090015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking Studies Unveil an Opportunity Against CORONA.
    Arif MN
    Comb Chem High Throughput Screen; 2022; 25(1):197-203. PubMed ID: 33231155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of bioactive molecule from
    Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity.
    Wang R; Chen X; Li H; Chen X; Sun D; Yu D; Lu J; Xie Y; Zhang Q; Xu J; Zhang W; Chen H; Liu S; Chen L
    Int J Biol Macromol; 2024 Feb; 257(Pt 2):128623. PubMed ID: 38070810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M
    Yang J; Lin X; Xing N; Zhang Z; Zhang H; Wu H; Xue W
    J Chem Inf Model; 2021 Aug; 61(8):3917-3926. PubMed ID: 34279924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
    Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
    Amin SA; Ghosh K; Gayen S; Jha T
    J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M
    Zhang K; Wang T; Li M; Liu M; Tang H; Wang L; Ye K; Yang J; Jiang S; Xiao Y; Xie Y; Lu M; Zhang X
    Eur J Med Chem; 2023 Sep; 257():115487. PubMed ID: 37257212
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M
    Sultan A; Ali R; Sultan T; Ali S; Khan NJ; Parganiha A
    Chronobiol Int; 2021 Jul; 38(7):971-985. PubMed ID: 33820462
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Docking-Based Evidence for the Potential of ImmunoDefender: A Novel Formulated Essential Oil Blend Incorporating Synergistic Antiviral Bioactive Compounds as Promising Mpro Inhibitors against SARS-CoV-2.
    Ksouri A; Klouz A; Bouhaouala-Zahar B; Moussa F; Bezzarga M
    Molecules; 2023 May; 28(11):. PubMed ID: 37298772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.
    Fink EA; Bardine C; Gahbauer S; Singh I; Detomasi TC; White K; Gu S; Wan X; Chen J; Ary B; Glenn I; O'Connell J; O'Donnell H; Fajtová P; Lyu J; Vigneron S; Young NJ; Kondratov IS; Alisoltani A; Simons LM; Lorenzo-Redondo R; Ozer EA; Hultquist JF; O'Donoghue AJ; Moroz YS; Taunton J; Renslo AR; Irwin JJ; García-Sastre A; Shoichet BK; Craik CS
    Protein Sci; 2023 Aug; 32(8):e4712. PubMed ID: 37354015
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors.
    Garland O; Ton AT; Moradi S; Smith JR; Kovacic S; Ng K; Pandey M; Ban F; Lee J; Vuckovic M; Worrall LJ; Young RN; Pantophlet R; Strynadka NCJ; Cherkasov A
    J Chem Inf Model; 2023 Apr; 63(7):2158-2169. PubMed ID: 36930801
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
    Isgrò C; Sardanelli AM; Palese LL
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
    Chakraborti S; Bheemireddy S; Srinivasan N
    Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.
    Ahmed MS; Farag AB; Boys IN; Wang P; Menendez-Montes I; Nguyen NUN; Eitson JL; Ohlson MB; Fan W; McDougal MB; Mar K; Thet S; Ortiz F; Kim SY; Solmonson A; Williams NS; Lemoff A; DeBerardinis RJ; Schoggins JW; Sadek HA
    Biomed Pharmacother; 2023 Jun; 162():114614. PubMed ID: 37068330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Studies of Cytotoxicity Effects, SARS-CoV-2 Main Protease Inhibition, and in Silico Interactions of Synthetic Chalcones.
    Guterres Fernandes OL; Tizziani T; Dambrós BP; Ferreira de Sousa N; Mansur Pontes CL; da Silva LAL; Escorteganha Pollo LA; de Assis FF; Scotti MT; Scotti L; Braga AL; Steindel M; Sandjo LP
    Chem Biodivers; 2023 Mar; 20(3):e202201151. PubMed ID: 36740573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Potential of Usnic-Acid-Based Thiazolo-Thiophenes as Inhibitors of the Main Protease of SARS-CoV-2 Viruses.
    Yarovaya OI; Filimonov AS; Baev DS; Borisevich SS; Zaykovskaya AV; Chirkova VY; Marenina MK; Meshkova YV; Belenkaya SV; Shcherbakov DN; Gureev MA; Luzina OA; Pyankov OV; Salakhutdinov NF; Khvostov MV
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacophore based virtual screening for natural product database revealed possible inhibitors for SARS-COV-2 main protease.
    El-Ashrey MK; Bakr RO; Fayed MAA; Refaey RH; Nissan YM
    Virology; 2022 May; 570():18-28. PubMed ID: 35339903
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19.
    Biernacki K; Ciupak O; Daśko M; Rachon J; Flis D; Budka J; Inkielewicz-Stępniak I; Czaja A; Rak J; Demkowicz S
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290910. PubMed ID: 38093611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.